scholarly journals 427: Supporting the Scleroderma Patient through a Complex Total Body Irradiation Preparative Regimen with Autolgous Stem Cell Support: A Multidisciplinary Approach

2008 ◽  
Vol 14 (2) ◽  
pp. 152
Author(s):  
D. Russell ◽  
M. Lassiter ◽  
J. Loftis
Keyword(s):  
Stem Cell ◽  
Total Body Irradiation ◽  
Multidisciplinary Approach ◽  
Stem Cell Support ◽  
Scleroderma Patient ◽  
Preparative Regimen ◽  
Total Body ◽  
Cell Support

scholarly journals Mesenchymal Stromal Cell-Derived Extracellular Vesicles Provide Long-Term Survival After Total Body Irradiation Without Additional Hematopoietic Stem Cell Support

Stem Cells ◽  
2017 ◽  
Vol 35 (12) ◽  
pp. 2379-2389 ◽  
Author(s):  
Jill-Sandra Schoefinius ◽  
Bärbel Brunswig-Spickenheier ◽  
Thomas Speiseder ◽  
Sabrina Krebs ◽  
Ursula Just ◽  
...  
Keyword(s):  
Stem Cell ◽  
Total Body Irradiation ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Term Survival ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Total Body ◽  
Cell Support

High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing’s Sarcoma Does Not Improve Prognosis

2001 ◽  
Vol 19 (11) ◽  
pp. 2812-2820 ◽  
Author(s):  
Paul A. Meyers ◽  
Mark D. Krailo ◽  
Marc Ladanyi ◽  
Ka-Wah Chan ◽  
Scott L. Sailer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Progressive Disease ◽  
Peripheral Blood Stem Cell ◽  
High Dose ◽  
Consolidation Therapy ◽  
Newly Diagnosed ◽  
Stem Cell Support ◽  
Total Body ◽  
High Dose Melphalan ◽  
Cell Support

PURPOSE: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing’s sarcoma (ES). PATIENTS AND METHODS: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support. RESULTS: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post–stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data. CONCLUSION: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.

Total Body Irradiation (TBI) Based Versus Chemotherapy-Based Preparative Regimens Before Autologous Stem Cell Transplant for Non-Hodgkin’s Lymphoma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5105-5105
Author(s):  
Hongwei Liu ◽  
Matthew Seftel ◽  
Allain Demers ◽  
Zoann Nugent ◽  
Garry Schroeder ◽  
...  
Keyword(s):  
Stem Cell ◽  
Total Body Irradiation ◽  
Disease Free Survival ◽  
Autologous Stem Cell Transplant ◽  
Rank Test ◽  
High Dose ◽  
Cell Transplant ◽  
Historical Cohort ◽  
Preparative Regimen ◽  
Total Body

Abstract OBJECTIVES: The optimum high dose preparative regimen for non-Hodgkin lymphoma (NHL) patients undergoing autologous stem cell transplantation (ASCT) is unknown. We compared the radiation-based regimen of cyclophosphamide, etoposide and 12 Gy total body irradiation (CY/E/TBI) to carmustine, etoposide, cytarabine and melphalan (BEAM) in NHL patients who received ASCT. We investigated acute and long-term toxicities, disease free survival (DFS), overall survival (OS) of these two regimens. METHODS: A historical cohort study was performed at a provincial cancer centre. Cause specific survival was determined with the Kaplan-Meier method. Survival between groups was compared using the log-rank test. RESULTS: From Mar-1991 to Sep-2005, 79 patients received CY/E/TBI (n=32) or BEAM (n=47). Histology was indolent in 30 and aggressive in 49 patients. Cell source was bone marrow in six and 73 received peripheral blood progenitor cells. Prior to ASCT, ten patients were in complete remission, 47 had chemo-sensitive disease and 22 had chemo-resistant disease. There were only two cases of interstitial pneumonitis, with one in each preparative regimen group. There were six transplant related deaths; two in the BEAM group and four were in TBI group. The TBI based group has a higher mean mucosits score (p=0.03). Five year DFS was 47% and 51% in the TBI and BEAM groups, respectively (p=0.41). Five year OS was 50% and 64% for the TBI and BEAM based groups (p=0.07). Multivariate analyzes revealed that patients with more advanced disease and raised LDH at ASCT independently predicted inferior DFS. There was one case of acute myeloid leukemia and two of prostate cancer, all of whom were in the TBI group. CONCLUSIONS: In this study, a 12 Gy TBI-based regimen resulted in a similar DFS but a trend toward poorer OS and higher second malignancies than a BEAM-based regimen. However, there did not appear to be excess pulmonary acute toxicities in the TBI based group.

Sign in / Sign up

Export Citation Format

Share Document